U.S. drug utilization management Market By Type (Prospective Review (pDUR), Concurrent Review (cDUR) and Retrospective Review (rDUR)), By Program Type (In-house and Outsourced), By End-use (PBMs, Health Plan Provider/Payors and Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Table of Content

• 1. Research Methodology and Data Source
  • 1.1. Methodology/Research Approach
  • 1.2. Market Size Estimation
  • 1.3. Market Breakdown and Data Triangulation
  • 1.4. Data Sources
  • 1.5. Secondary Sources
  • 1.6. Primary Sources
• 2. Executive Summary
  • 2.1. Taxonomy
  • 2.2. Market Outlook
  • 2.3. Key Facts and Figures
  • 2.4. Major Players in U.S. drug utilization management Market
• 3. Market Overview
  • 3.1. Industry Overview
  • 3.2. Segmental Overview
  • 3.3. Market Dynamics
  • 3.3.1. Drivers
  • 3.3.2. Restraints
  • 3.3.3. Opportunities
  • 3.3.4. Trends
  • 3.4. Regulatory Framework
  • 3.5. Opportunity Map Analysis
  • 3.6. Opportunity Orbits
  • 3.7. Market Investment Feasibility Index
  • 3.8. PESTLE Analysis
  • 3.9. PORTER’S Five Force Analysis
  • 3.10. Drivers & Restraints Impact Analysis
  • 3.11. Patient Journey Mapping
  • 3.12. Technological Landscape
  • 3.13. Product Life Cycle Analysis
  • 3.14. Value Chain Analysis
  • 3.14.1. List of Raw Material Suppliers
  • 3.14.2. List of U.S. drug utilization management Manufacturers
  • 3.14.3. List of Dealer/Distributors
  • 3.14.4. List of Potential Customers
  • 3.15. Cost Structure Analysis
• 4. Macro-economic Factors
• 5. Impact of Current Geopolitical Scenario
• 6. U.S. drug utilization management Market Analysis and Forecast, By Type
  • 6.1. Key Findings
  • 6.2. U.S. drug utilization management Market Size Value (US$ Mn) Forecast, By Type, 2020-2035
  • 6.2.1. Prospective Review
  • 6.2.2. Concurrent Review
  • 6.2.3. Retrospective Review
  • 6.3. U.S. drug utilization management Market Attractiveness Analysis, By Type
• 7. U.S. drug utilization management Market Analysis and Forecast, By Program Type
  • 7.1. Key Findings
  • 7.2. U.S. drug utilization management Market Size Value (US$ Mn) Forecast, By Program Type, 2020-2035
  • 7.2.1. In-House
  • 7.2.2. Outsourced
  • 7.3. U.S. drug utilization management Market Attractiveness Analysis, By Program Type
  • 8. U.S. drug utilization management Market Analysis and Forecast, By End-Use
  • 8.1. Key Findings
  • 8.2. U.S. drug utilization management Market Size Value (US$ Mn) Forecast, By End-Use, 2020-2035
  • 8.2.1. PBMs
  • 8.2.2. Health Plan Provider/Payors
  • 8.2.3. Pharmacies
  • 8.3. U.S. drug utilization management Market Attractiveness Analysis, By End-Use
• 9. Competitive Landscape & Company Profiles
  • 9.1. Market Competition Scenario Analysis, By Company
  • 9.2. Competitor Landscape
  • 9.3. Company Share Analysis
  • 9.4. Company Profiles
    • 9.4.1. Prime Therapeutics LLC
      • 9.4.1.1. Company Details
      • 9.4.1.2. Business Overview
      • 9.4.1.3. Product Portfolio
      • 9.4.1.4. Financial Insights
      • 9.4.1.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.1.6. SWOT Analysis
      • 9.4.1.7. Geographic Footprint
    • 9.4.2. MedicusRx
      • 9.4.2.1. Company Details
      • 9.4.2.2. Business Overview
      • 9.4.2.3. Product Portfolio
      • 9.4.2.4. Financial Insights
      • 9.4.2.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.2.6. SWOT Analysis
      • 9.4.2.7. Geographic Footprint
    • 9.4.3. EmblemHealth
      • 9.4.3.1. Company Details
      • 9.4.3.2. Business Overview
      • 9.4.3.3. Product Portfolio
      • 9.4.3.4. Financial Insights
      • 9.4.3.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.3.6. SWOT Analysis
      • 9.4.3.7. Geographic Footprint
    • 9.4.4. Optum, Inc
      • 9.4.4.1. Company Details
      • 9.4.4.2. Business Overview
      • 9.4.4.3. Product Portfolio
      • 9.4.4.4. Financial Insights
      • 9.4.4.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.4.6. SWOT Analysis
      • 9.4.4.7. Geographic Footprint
    • 9.4.5. Point32Health, Inc
      • 9.4.5.1. Company Details
      • 9.4.5.2. Business Overview
      • 9.4.5.3. Product Portfolio
      • 9.4.5.4. Financial Insights
      • 9.4.5.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.5.6. SWOT Analysis
      • 9.4.5.7. Geographic Footprint
    • 9.4.6. AssureCare LLC
      • 9.4.6.1. Company Details
      • 9.4.6.2. Business Overview
      • 9.4.6.3. Product Portfolio
      • 9.4.6.4. Financial Insights
      • 9.4.6.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.6.6. SWOT Analysis
      • 9.4.6.7. Geographic Footprint
    • 9.4.7. MindRx Group
      • 9.4.7.1. Company Details
      • 9.4.7.2. Business Overview
      • 9.4.7.3. Product Portfolio
      • 9.4.7.4. Financial Insights
      • 9.4.7.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.7.6. SWOT Analysis
      • 9.4.7.7. Geographic Footprint
    • 9.4.8. Agadia Systems, Inc
      • 9.4.8.1. Company Details
      • 9.4.8.2. Business Overview
      • 9.4.8.3. Product Portfolio
      • 9.4.8.4. Financial Insights
      • 9.4.8.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.8.6. SWOT Analysis
      • 9.4.8.7. Geographic Footprint
    • 9.4.9. Elevance Health (CarelonRx)
      • 9.4.9.1. Company Details
      • 9.4.9.2. Business Overview
      • 9.4.9.3. Product Portfolio
      • 9.4.9.4. Financial Insights
      • 9.4.9.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.9.6. SWOT Analysis
      • 9.4.9.7. Geographic Footprint
    • 9.4.10. ExlService Holdings, Inc.
      • 9.4.10.1. Company Details
      • 9.4.10.2. Business Overview
      • 9.4.10.3. Product Portfolio
      • 9.4.10.4. Financial Insights
      • 9.4.10.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.10.6. SWOT Analysis
      • 9.4.10.7. Geographic Footprint
    • 9.4.11. MRIoA
      • 9.4.11.1. Company Details
      • 9.4.11.2. Business Overview
      • 9.4.11.3. Product Portfolio
      • 9.4.11.4. Financial Insights
      • 9.4.11.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.11.6. SWOT Analysis
      • 9.4.11.7. Geographic Footprint
    • 9.4.12. S&C Technologies, Inc.
      • 9.4.12.1. Company Details
      • 9.4.12.2. Business Overview
      • 9.4.12.3. Product Portfolio
      • 9.4.12.4. Financial Insights
      • 9.4.12.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.12.6. SWOT Analysis
      • 9.4.12.7. Geographic Footprint
    • 9.4.13. In-House Providers
      • 9.4.13.1. Company Details
      • 9.4.13.2. Business Overview
      • 9.4.13.3. Product Portfolio
      • 9.4.13.4. Financial Insights
      • 9.4.13.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.13.6. SWOT Analysis
      • 9.4.13.7. Geographic Footprint
    • 9.4.14. Ultimate Health Plans
      • 9.4.14.1. Company Details
      • 9.4.14.2. Business Overview
      • 9.4.14.3. Product Portfolio
      • 9.4.14.4. Financial Insights
      • 9.4.14.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 9.4.14.6. SWOT Analysis
      • 9.4.14.7. Geographic Footprint

List of Tables

• Table 1: U.S. drug utilization management Market Value (US$ Mn), By Type, 2020-2035
• Table 2: U.S. drug utilization management Market Value (US$ Mn), By Program Type, 2020-2035
• Table 3: U.S. drug utilization management Market Value (US$ Mn), By End-Use, 2020-2035

List of Figures

• Figure 1: U.S. drug utilization management Market Value (US$ Mn), 2020-2035
• Figure 2: U.S. drug utilization management Market Value Share (%) Analysis, By Type, 2025 & 2035
• Figure 3: U.S. drug utilization management Market Value Share (%) Analysis, By Program Type, 2025 & 2035
• Figure 4: U.S. drug utilization management Market Value Share (%) Analysis, By End-Use, 2025 & 2035
• Figure 5: U.S. drug utilization management Market Value Share (%) Analysis, By Type, 2020, 2025 and 2035
• Figure 6: U.S. drug utilization management Market Attractiveness Analysis, By Type
• Figure 7: U.S. drug utilization management Market Value Share (%) Analysis, By Program Type, 2020, 2025 and 2035
• Figure 8: U.S. drug utilization management Market Attractiveness Analysis, By Program Type
• Figure 9: U.S. drug utilization management Market Value Share (%) Analysis, By End-Use, 2020, 2025 and 2035
• Figure 10: U.S. drug utilization management Market Attractiveness Analysis, By End-Use